Reports Q1 revenue $1.41B, consensus $1.4B. “The many milestones achieved this quarter are the result of our structural heart-focused strategy and our decades of unwavering dedication to driving breakthrough innovation in pioneering and leading categories. Collectively, these milestones mark the significant progress we have made to unlock this large and growing opportunity to transform care for millions of structural heart patients around the world,” said Bernard Zovighian, CEO. “We are pleased with our strong start to the year and have confidence in our 2025 outlook. Looking to the future, we will build on the many impactful catalysts for our company, which position us for distinguished growth in the years ahead.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Notable companies reporting after market close
- Is EW a Buy, Before Earnings?
- Edwards says eight-year data confirm long-term durability of Resilia tissue
- Hold Rating Maintained for Edwards Lifesciences Amidst Positive Developments in Mitral Valve Approval and TAVR Challenges
- Balanced Outlook on Edwards Lifesciences Amid TMTT Growth and TAVR Market Challenges